Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ARG1 | P05089 | 1/20 | 0.49 |
| ▸ | ARG2 | P78540 | 1/20 | 0.49 |
| ▸ | PARP1 | P09874 | 1/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.32 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1360119 | 1.00 | ARG1 (0.49) | ARG1ARG2PARP1SLC6A2SLC6A4 | |
| Hydrochloric Acid SCHEMBL30382824 | 0.98 | ARG1 (0.47) | ARG1ARG2PARP1SLC6A2SLC6A4 | |
| Hydrochloric Acid SCHEMBL4684924 | 0.98 | ARG1 (0.47) | ARG1ARG2PARP1SLC6A2SLC6A4 | |
| Ethylene Glycol SCHEMBL28530734 | 0.95 | ARG1 (0.45) | ARG1ARG2PARP1SLC6A2SLC6A4 | |
| SCHEMBL21645480 | 0.93 | ARG1 (0.43) | ARG1ARG2PARP1MEN1ALDH1A1 | |
| SCHEMBL28516379 | 0.83 | ARG1 (0.37) | ARG1ARG2 | |
| SCHEMBL14265250 | 0.82 | ARG1 (0.54) | ARG1ARG2SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL12764363 | 0.81 | ARG1 (0.36) | ARG1ARG2PARP1SLC6A2SLC6A4 | |
| SCHEMBL8190743 | 0.81 | ARG1 (0.36) | ARG1ARG2PARP1SLC6A2SLC6A4 | |
| Hydrochloric Acid SCHEMBL1359302 | 0.80 | ARG1 (0.35) | ARG1ARG2PARP1SLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110118239-A1 | PREPARATION AND ENANTIOMERIC SEPARATION OF 7-(3-PYRIDINYL)-1,7-DIAZASPIRO[4.4]NONANE AND NOVEL SALT FORMS OF THE RACEMATE AND ENANTIOMERS | TARGACEPT, INC. (US) | 2011-05-19 | — | — | US | claimed |
| JP-2011509933-A | — | — | 2011-03-31 | — | — | JP | claimed |
| EP-2242364-A1 | PREPARATION AND ENANTIOMERIC SEPARATION OF 7-(3-PYRIDINYL)-1,7-DIAZASPIROÝ4.4¨NONANE AND NOVEL SALT FORMS OF THE RACEMATE AND ENANTIOMERS | Targacept Inc. (US) | 2010-10-27 | — | — | EP | claimed |
| WO-2009091561-A1 | PREPARATION AND ENANTIOMERIC SEPARATION OF 7-(3-PYRIDINYL)-1,7-DIAZASPIRO[4.4] NONANE AND NOVEL SALT FORMS OF THE RACEMATE AND ENANTIOMERS | TARGACEPT, INC. (US) | 2009-07-23 | — | — | WO | claimed |
| CN-121930151-A | (R) -2-allyl pyrrolidine-2-carboxylic acid and chiral purification method thereof | 杭州澳赛诺医药技术有限公司 | 2026-04-28 | — | — | CN | disclosed |
| CN-121930151-A | (R) -2-allyl pyrrolidine-2-carboxylic acid and chiral purification method thereof | 杭州澳赛诺医药技术有限公司 | 2026-04-28 | — | — | CN | disclosed |
| US-20250367192-A1 | BICYCLIC COMPOUNDS AND METHODS FOR THEIR USE IN TREATING PITT HOPKINS SYNDROME | NEUREN PHARMACEUTICALS LTD (NZ) | 2025-12-04 | — | — | US | disclosed |
| US-20250367192-A1 | BICYCLIC COMPOUNDS AND METHODS FOR THEIR USE IN TREATING PITT HOPKINS SYNDROME | NEUREN PHARMACEUTICALS LTD (NZ) | 2025-12-04 | — | — | US | disclosed |
| US-12472177-B2 | Bicyclic compounds and methods for their use in treating Pitt Hopkins syndrome | NEUREN PHARMACEUTICALS LIMITED (NZ) | 2025-11-18 | — | — | US | disclosed |
| US-12472177-B2 | Bicyclic compounds and methods for their use in treating Pitt Hopkins syndrome | NEUREN PHARMACEUTICALS LIMITED (NZ) | 2025-11-18 | — | — | US | disclosed |
| US-20230301994-A9 | BICYCLIC COMPOUNDS AND METHODS FOR THEIR USE IN TREATING PITT HOPKINS SYNDROME | NEUREN PHARMACEUTICALS LIMITED (NZ) | 2023-09-28 | — | — | US | disclosed |
| US-20230301994-A9 | BICYCLIC COMPOUNDS AND METHODS FOR THEIR USE IN TREATING PITT HOPKINS SYNDROME | NEUREN PHARMACEUTICALS LIMITED (NZ) | 2023-09-28 | — | — | US | disclosed |
| US-20060258663-A1 | Cyclic G-2AllylProline in treatment of Parkinson's disease | NEUREN PHARMACEUTICALS LIMITED (NZ) | 2006-11-16 | — | — | US | disclosed |
| EP-1664050-A2 | NEUROPROTECTIVE BICYCLIC COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Neuren Pharmaceuticals Limited (NZ) | 2006-06-07 | — | — | EP | disclosed |
| US-7041314-B2 | GPE analogs and peptidominetics | NEUREN PHARMACEUTICALS LTD. (NZ) | 2006-05-09 | — | — | US | disclosed |
| WO-2005023815-A2 | NEUROPROTECTIVE BICYCLIC COMPOUNDS AND METHODS FOR THEIR USE | NEUREN PHARMACEUTICALS LIMITED (NZ) | 2005-03-17 | — | — | WO | disclosed |
| EP-1401808-A4 | GPE ANALOGS AND PEPTIDOMIMETICS | NEURONZ LTD (NZ) | 2004-08-25 | — | — | EP | disclosed |
| EP-1401808-A2 | GPE ANALOGS AND PEPTIDOMIMETICS | Neuronz Limited (NZ) | 2004-03-31 | — | — | EP | disclosed |
| US-20030055004-A1 | GPE analogs and peptidominetics | NEUREN PHARMACEUTICALS LIMITED (AU) | 2003-03-20 | — | — | US | disclosed |
| WO-2002094856-A2 | GPE ANALOGS AND PEPTIDOMIMETICS | NEURONZ LIMITED (NZ) | 2002-11-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250367192-A1 | BICYCLIC COMPOUNDS AND METHODS FOR THEIR USE IN TREATING PITT HOPKINS SYNDROME | QPCT, GRIA2, GGPS1 | ARG1 3992/4885ARG2 2793/4885PARP1 3855/4885 |
| US-20030055004-A1 | GPE analogs and peptidominetics | GLUL, GCG, BAD | ARG1 353/4885ARG2 278/4885PARP1 1466/4885 |
| US-20230301994-A9 | BICYCLIC COMPOUNDS AND METHODS FOR THEIR USE IN TREATING PITT HOPKINS SYNDROME | QPCT, GRIA2, GGPS1 | ARG1 3992/4885ARG2 2793/4885PARP1 3855/4885 |
| US-12472177-B2 | Bicyclic compounds and methods for their use in treating Pitt Hopkins syndrome | QPCT, GRIA2, GGPS1 | ARG1 3992/4885ARG2 2793/4885PARP1 3855/4885 |
| US-20060258663-A1 | Cyclic G-2AllylProline in treatment of Parkinson's disease | PARK7, ADCYAP1R1, LRRK2 | ARG1 2471/4885ARG2 389/4885PARP1 994/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.